# Core B - Specimen Database.

> **NIH NIH P01** · WASHINGTON UNIVERSITY · 2022 · $128,652

## Abstract

CORE B SUMMARY/ABSTRACT
The main objective of this Core is to provide expert pathology services, in coordination with prospective
processing, database tracking, storage, and optimal distribution of serial biospecimens from AML and
MDS patients to support Core C and all 4 of the GAML Projects. After enrollment of AML and MDS patients
by Core A (Clinical Database), bone marrow, peripheral blood leukocytes, serum/plasma, skin, and oral mucosa
biospecimens are processed and banked by Core B (Specimen Database). These specimens and their
derivatives will serve as the basis for genome and transcriptome analyses and immunological assays in Core C
(Sequencing and Analysis) and Projects 1-4. This Biobanking Core will maintain and expand its
comprehensive database that annotates each specimen with information related to histopathology, disease
status, date collected/processed/distributed, processing performed, parent/derived specimen linkage, quantity,
quality, and availability. All specimens are anonymously linked to the patient of origin through unique patient
identifier numbers. Pathology expertise provided by Core B ensures the diagnostic accuracy of patient
specimens, optimal selection of malignant and normal tissues, and maintenance of quality control (QC) and
quality assurance (QA) standards and procedures within a CAP-accredited laboratory environment.
Specific Aim/Core Service 1:
We will prospectively process, annotate, and store serial biospecimens and derivatives from all AML and
MDS patients enrolled on the GAML protocol. Procedures that are customized and validated for GAML
Projects will be used. Viably cryopreserved cells will be banked for single cell RNA-seq, culture expansion, flow
cytometry, and immunologic assays. We will isolate high quality DNA/RNA for genome, epigenome and
transcriptome studies.
Specific Aim/Core Service 2:
We will provide expert pathology review and database tracking to identify and distribute biospecimens
for GAML studies. Core B will use its biospecimen database to provide histopathology, disease status, quality,
quantity, and availability data in real-time to enable optimal utilization the GAML Projects and Core C.
Histopathology services and pathology review will ensure accurate diagnostic information, provide
macro/microdissection of archived tissues, and optimal specimen selection and assembly of pathological subsets
for GAML Projects.

## Key facts

- **NIH application ID:** 10311214
- **Project number:** 5P01CA101937-18
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Jacqueline E. Payton
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $128,652
- **Award type:** 5
- **Project period:** 2003-09-19 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10311214

## Citation

> US National Institutes of Health, RePORTER application 10311214, Core B - Specimen Database. (5P01CA101937-18). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10311214. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*